Preview

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

Профилактика и лечение тошноты и рвоты у детей и подростков, получающих противоопухолевую терапию. Текущее состояние и потенциальные пути улучшения

https://doi.org/10.24287/1726-1708-2020-19-4-205-223

Полный текст:

Аннотация

Несмотря на то, что тошнота и рвота (ТИР), индуцированные цитостатической терапией, редко носят жизнеугрожающий характер, с точки зрения пациентов, это одно из наиболее тяжело переносимых осложнений, зачастую имеющее мучительный характер. Кроме того, ТИР могут усугублять течение других осложнений и патологических состояний. Современная антиэметическая профилактика позволяет значительно снизить частоту развития ТИР у детей и подростков, получающих противоопухолевую терапию, однако до настоящего времени в детской популяции неадекватный контроль ТИР наблюдается значимо чаще, чем у взрослых, а арсенал противорвотных препаратов в силу регуляторных особенностей исследований лекарственных средств в детской практике обновляется с запозданием. Целью данной статьи является ознакомление с современными стандартами профилактики и лечения ТИР у детей и подростков, а также с возможными путями их совершенствования.

Об авторах

Н. В. Жуков
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России; ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Россия
Москва


Л. Л. Казакова
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия

Казакова Лилия Леонидовна, врач-детский онколог отделения гематологии и онкологии старшего возраста и нейроонкологии

117997, Москва, ул. Саморы Машела, 1



Г. А. Новичкова
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
Москва


Список литературы

1. Жуков Н.В. Профилактика тошноты и рвоты, обусловленных проведением химиотерапии и лучевой терапии. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2010; 9 (2): 13–22.

2. Baxter A., Watcha M., Baxter W., Leong T., Wyatt M. Development and validation of a pictorial nausea rating scale for children. Pediatrics 2011; 127 (6): e1542–9. DOI: 10.1542/peds.2010-1410

3. Dupuis L.L., Taddio A., Kerr E.N., Kelly A., MacKeigan L. Development and validation of a pediatric nausea assessment tool (PeNAT) for use by children receiving antineoplastic agents. Pharmacotherapy 2006; 26 (9): 1221–31. DOI: 10.1592/phco.26.9.1221

4. Paw Cho Sing E., Robinson P.D., Flank J., Holdsworth M., Thackray J., Freedman J., et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. Pediatr Blood Cancer 2019; 66 (5): e27646. DOI: 10.1002/pbc.27646

5. Patel P., Robinson P.D., Thackray J., Flank J., Holdsworth M.T., Gibson P., et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatr Blood Cancer 2017; 64 (10). DOI: 10.1002/pbc.26542

6. Dupuis L.L., Robinson P.D., Boodhan S., Holdsworth M., Portwine C., Gibson P., et al. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. Pediatr Blood Cancer 2014; 61 (8): 1506–12. DOI: 10.1002/pbc.25063

7. Flank J., Robinson P.D., Holdsworth M., Phillips R., Portwine C., Gibson P., et al. Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer. Pediatr Blood Cancer 2016; 63 (7): 1144–51. DOI: 10.1002/pbc.25955

8. Hesketh P.J., Kris M.G., Basch E., et al. Antiemetics: ASCO Guideline Update [published online ahead of print, 2020 Jul 13]. J Clin Oncol 2020. DOI: 10.1200/JCO.20.01296

9. Dupuis L., Boodhan S., Sung L., Portwine C., Hain R., McCarthy P., et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 2011; 57 (2): 191–8. DOI: 10.1002/pbc.23114

10. De Mulder P.H., Seynaeve C., Vermorken J.B., van Liessum P.A., MolsJevdevic S., AllmanE.L., et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113 (11): 834–40. DOI: 10.7326/0003-4819-113-11-834

11. Olver I., Paska W., Depierre A., Seitz J.F., Stewart D.J., Goedhals L., et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol 1996; 7 (9): 945–52. DOI: 10.1093/oxfordjournals.annonc.a010798

12. Warr D.G., Street J.C., Carides A.D. Evaluation of risk factors predictive of nausea and vomiting with current standardof-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy. Support Care Cancer 2011; 19 (6): 807–13. DOI: 10.1007/s00520-010-0899-5

13. Hesketh P.J, Aapro M., Street .J, Carides A.D. Evaluation of risk factors predictive of nausea and vomitingwith current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 2010; 18 (9): 1171–7. DOI: 10.1007/s00520-009-0737-9

14. Roscoe J.A., Bushunnow P., Morrow G.R., Hickok J.T., Kuebler P.J., Jacobs A., et al. Patient experience is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 2004; 101 (11): 2701–8. DOI: 10.1002/cncr.20718

15. Dupuis L.L., Tamura R.N., Kelly K.M., Krischer J.P., Langevin A.M., Chen L., et al. Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy. Pediatr Blood Cancer 2019; 66: e27584.

16. Leslie R.A., Shah Y., Thejomayen M., Murphy K.M., Robertson H.A. The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting. Can J Physiol Pharmacol 1990; 68 (2): 279–88. DOI: 10.1139/y90-042

17. Endo T., Minami M., Hirafuji M., Ogawa T., Akita K., Nemoto M., et al. Neurochemistry and neuropharmacology of emesis – the role of serotonin. Toxicology 2000; 153 (1–3): 189–201. DOI: 10.1016/s0300-483x(00)00314-0

18. Tricco A.C., Blondal E., Veroniki A.A., Soobiah C., Vafaei A., Ivory J., et al. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Med 2016; 14 (1): 216. DOI: 10.1186/s12916-015-0379-3

19. Kovács G., Wachtel A.E., Basharova E.V., Spinelli T., Nicolas P., Kabickova E. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, noninferiority study. Lancet Oncol 2016; 17 (3): 332–44. DOI: 10.1016/S1470-2045(15)00520-3

20. Chaudhary N.K., John R.R., Boddu D., Mahasampath G., Nesadeepam N., Mathew L.G. Palonosetron is a better choice compared with ondansetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in a resource-limited pediatric oncology center: results from a randomized control trial. J Pediatr Hematol Oncol 2019; 41 (4): 294–7. DOI: 10.1097/MPH.0000000000001357

21. Tan J., Wang S., Liang X., Li C.C., Zhang J., Zhao Z., et al. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy. Pediatr Blood Cancer 2018; 65 (2). DOI: 10.1002/pbc.26815

22. Alvarez O., Freeman A, Bedros A, Call S.K., Volsch J, et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995; 17 (2): 145–50. DOI: 10.1097/00043426-199505000-00008

23. Phillips R., Gopaul S., Gibson F., et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev 2010; 1–87. Art. No.: CD007786. DOI: 10.1002/14651858.CD007786.pub2

24. The Italian Group for Antiemetic Research. Double-blind, dosefinding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998; 16 (9): 2937– 42. DOI: 10.1200/JCO.1998.16.9.2937

25. The Italian Group for Antiemetic Research. Randomized, doubleblind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004; 22 (4): 725–9. DOI: 10.1200/JCO.2004.09.040

26. Roila F., Ruggeri B., Ballatori E., del Favero A., Tonato M. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized doubleblind study. J Clin Oncol 2014; 32 (2): 101–6.

27. Hesketh P.J., Grunberg S.M., Gralla R.J., Warr D.G., Roila F., deWit R., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112–9.

28. Warr D.G., Hesketh P.J., Gralla R.J., Muss H.B., Herrstedt J., Eisenberg P.D., et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822–30.

29. Gore L., Chawla S., Petrilli A., Hemenway M., Schissel D., Chua V., et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009; 52: 242–7.

30. Aapro M.S., Walko C.M. Aprepitant: drug– drug interactions in perspective. Ann Oncol 2010; 21 (12): 2316–23.

31. Hashimoto H., Abe M., Tokuyama O., Mizutani H., Uchitomi Y., Yamaguchi T., et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol 2020; 21 (2): 242–9. DOI: 10.1016/S1470-2045(19)30678-3

32. Kris M.G., Hesketh P.J., Somerfield M.R., Feyer P., Clark-Snow R., Koeller J.M., et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24 (18): 2932–47. DOI: 10.1200/JCO.2006.06.9591

33. Ettinger D.S., Bierman P.J., Bradbury B., Comish C.C., Ellis G., Ignoffo R.J., et al. Antiemesis. J Natl Compr Cancer Netw 2007; 5 (1): 12–33. DOI: 10.6004/jnccn.2007.0004

34. Roila F., Hesketh P.J., Herrstedt J.; Antiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20–8.

35. Herrstedt J. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2007; 18 (Suppl 2): ii83–5.

36. Hesketh P.J., Grunberg S.M., Gralla R.J., Warr D.G., Roila F.,de Wit R., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21 (22): 4112–9. DOI:10.1200/JCO.2003.01.095

37. Poli-Bigelli S., Rodrigues-Pereira J., Carides A.D., Ma G.J., Eldridge K., Hipple A., et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97 (12): 3090–8. DOI: 10.1002/cncr.11433

38. dos Santos L.V., Souza F.H., Brunetto A.T., Sasse A.D., da Silveira Nogueira Lima J.P. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 2012; 104 (17): 1280–92. DOI: 10.1093/jnci/djs335

39. Dupuis L., Boodhan S., Holdsworth M., Robinson P.D., Hain R., Portwine C., et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 2013; 60 (7): 1073– 82. DOI: 10.1002/pbc.24508

40. Bakhshi S., Batra A., Biswas B., Dhawan D., Paul R., Sreenivas V. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 2015; 23 (11): 3229–37. DOI:10.1007/s00520-015- 2714-9

41. Kang H.J., Loftus S., Taylor A., DiCristina C., Green S., Zwaan C.M. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16 (4): 385–94. DOI:10.1016/S1470-2045(15)70061-6

42. Small B.E., Holdsworth M.T., Raisch D.W., Winter S.S. Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol 2000; 22: 125–32.

43. Dupuis L.L., Nathan P.C. Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines. Paediatr Drugs 2010; 12: 51–61.

44. Holdsworth M.T., Raisch D.W., Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006; 106: 931–40.

45. Kovacs G., Wachtel A.E., Basharova E.V., Spinelli T., Nicolas P., Kabickova E. Palonosetron versus ondansetron for prevention of chemotherapyinduced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. Lancet Oncol 2016; 17 (3): 332–44.

46. Nadaraja S., Mamoudou A.D., Thomassen H., Wehner P.S., Rosthoej S., Schroeder H. Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate. Pediatr Blood Cancer 2012; 59 (5): 870–3.

47. Patil V., Prasada H., Prasad K., Shenoy U.V. Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children. J Community Support Oncol 2015; 13 (6): 209–13.

48. Ripaldi M., Parasole R., De Simone G., D'Amico M.R., Migliorati R., Zanotta G., et al. Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety. Bone Marrow Transplant 2010; 45 (11): 1663–4. DOI: 10.1038/bmt.2010.23

49. Varrasso G., De Grazia A., Mollace M.G., Megaro G., Paiano M., Suraci S. Antiemetic efficacy of palonosetron in children receiving moderately emetogenic chemotherapy: preliminary results. Pediatr Blood Cancer 2013; 60: 174.

50. Bymaster F.P., Falcone J.F., Bauzon D., Kennedy J.S., Schenck K., DeLapp N.W., et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 2001; 430 (23): 341–9. DOI:10.1016/S0014-2999(01)01399-1

51. Srivastava M., Brito-Dellan N., Davis M.P., Leach M., Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003; 25 (6): 578–782. DOI: 10.1016/S0885-3924(03)00143-X

52. Navari R.M., Gray S.E., Kerr A.C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9: 188–95.

53. Zhang Z., Zhang Y., Chen G., Hong S., Yang Y. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor AntagonistBased Triple Regimens in Preventing ChemotherapyInduced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. Oncologist 2018; 23 (5): 603–16.

54. Navari R.M., Qin R., Ruddy K.J., Liu H., Powell S.F., Bajaj M., et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016; 375 (2): 134–142. DOI: 10.1056/NEJMoa1515725

55. Hesketh P.J., Kris M.G., Basch E., Bohlke K., Barbour S.Y., Clark-Snow R.A., et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017; 35 (28): 3240– 61. DOI:10.1200/JCO.2017.74.4789

56. Basch E., Prestrud A.A., Hesketh P.J., Kris M.G., Feyer P.C., Somerfield M.R., et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2011; 29: 4189–98.

57. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008; 5 (1): 32–43. DOI: 10.1038/ncponc1021

58. Roila F., Molassiotis A., Herrstedt J., Aapro M., Gralla R.J., Bruera E., et al. 2016 MASCC and ESMO guideline update for the prvention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27 (Suppl 5): v119–33. DOI: 10.1093/annonc/mdw270

59. Hashimoto H., Abe M., Tokuyama O., et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21 (2): 242–9. DOI: 10.1016/S1470-2045(19)30678-3

60. Samsel C., Kearney J., Meadows A.L., Abrams A., Hirst J.M., Muriel A.C. Olanzapine for chemotherapy-induced nausea:Lessons learned from child and adolescent psychiatry. Pediatr Blood Cancer 2018; 65 (10): e27289. DOI:10.1002/pbc.27289

61. Flank J., Sung L., Dvorak C.C., Spettigue W., Dupuis L.L. The safety of olanzapine in young children: a systematic review and meta-analysis. Drug Saf 2014; 37 (10): 791–804. DOI: 10.1007/s40264-014-0219-y

62. Flank J., Thackray J., Nielson D., August A., Schechter T., Alexander S., et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in: A retrospective, multi-center review. Pediatr Blood Cancer 2015; 62: 496–501.

63. Radhakrishnan V., Pai V., Rajaraman S., Mehra N., Ganesan T. , Dhanushkodi M., et al. Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial. Pediatr Blood Cancer 2020: e28532. DOI: 10.1002/pbc.28532.

64. Flank J., Schechter T., Gibson P., Johnston D.L., Orsey A.D., Portwine C., et al. Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study. Support Care Cancer 2018; 26: 549–55. DOI: 10.1007/s00520-017-3864-8

65. Naik R.D., Vishnubhatla S., Singh V., Pillai A.S., Dhawan D., Bakhshi S. Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial. J Clin Oncol 2020; 38 (32): 3785-93. doi: 10.1200/JCO.20.00871


Для цитирования:


Жуков Н.В., Казакова Л.Л., Новичкова Г.А. Профилактика и лечение тошноты и рвоты у детей и подростков, получающих противоопухолевую терапию. Текущее состояние и потенциальные пути улучшения. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020;19(4):205-223. https://doi.org/10.24287/1726-1708-2020-19-4-205-223

For citation:


Zhukov N.V., Kazakova L.L., Novichkova G.A. The prevention and treatment of chemotherapy-induced nausea and vomiting in children and adolescents receiving cancer treatment: the current status and possibilities for improvement. Pediatric Hematology/Oncology and Immunopathology. 2020;19(4):205-223. (In Russ.) https://doi.org/10.24287/1726-1708-2020-19-4-205-223

Просмотров: 70


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)